Drugs are moving from "one molecule, one drug" to a new era of "one platform for one class of diseases, one algorithm for one class of patients, one manufacturing system for countless individualized products, and one Bio-OS (Biological Operating System)."

Chapter 1: Moderna's Phase III Trial "Explodes"

On August 19, Moderna/Merck announced the Phase III INTerpath-001 results. The trial enrolled 1,137 high-risk melanoma patients. The individualized mRNA vaccine Intismeran Autogene (V940/mRNA-4157) in combination with Keytruda met both recurrence-free survival and distant metastasis-free survival endpoints. Full data are yet to be released, but this represents the most important validation to date for an individualized mRNA cancer vaccine to reach Phase III.

The next day, Moderna's stock soared 155%, jumping from $64.3 to $177.26! Across the Atlantic, China's innovative drug index followed with a sharp rally...

AI once again demonstrated its potential in the life sciences. Moderna itself has long made this clear: its individualized vaccine system connects sequencing, AI-powered neoantigen selection, mRNA design, manufacturing, and clinical delivery; AI can even continuously learn from clinical and immunogenicity data.

The true economic value of this trial is no longer a single mRNA sequence, but a "biological operating system" capable of continuously generating new drugs. Moderna has not just changed one drug — it has changed "the definition of a drug."

The basic unit of traditional pharmaceutical economics is: Drug = Molecule + Manufacturing + Clinical Trial + Approval

What Moderna has demonstrated may be: Drug = Biological Platform + Data/AI + Patient Genomics + Manufacturing + Clinical Algorithm. A drug is no longer a "product," but a "system."

Chapter 2: Bio-OS Moves Drug Innovation from "Product Economy" to "Platform Economy"

In the past: R&D on one drug → failure/success → R&D on the next drug. This is the classic product economy.

Drug innovation followed the "three ten" law — 10 years, $1 billion, 10% success rate — and Eroom's Law, where the number of new drugs produced per $1 billion halves every nine years.

In the future, it could become: Build Bio-OS → continuously input disease data → AI design → clinical validation → automated manufacturing → generate new therapies.

The innovation function may shift from gambling on one drug at a time, to a platform that places continuous bets — with each bet increasing the probability of success for the next. Is this the right direction to reverse Eroom's Law?

Reducing drug R&D costs may not be about "making a single clinical trial cheaper," but about giving the entire innovation system learning capabilities. This is where Bio-OS's most值得讨论 economic implications lie.

Chapter 3: Bio-OS Creates a New Division of Labor in Drug Innovation

China's innovative drug industry is rising rapidly, moving from "Great Nation New Drugs" to "New Drug Great Nation." Amid the turbulent waves of this paradigm revolution, we must recognize that the U.S. still possesses irreplaceable advantages, while China is becoming an indispensable player in global drug innovation.

America's advantages lie in: original science + AI + biotech platforms + FDA + global capital + MNC commercialization + global pricing systems.

China's advantages lie in: engineering talent dividend + large-scale clinical resources + patient data + IIT capabilities + rapid clinical development + CMC engineering + large-scale manufacturing.

So the future may not be a simple division of "U.S. discovers, China develops, U.S. commercializes." Driven by personalized medicine and platform economics, once an AI-centric Bio-OS takes shape, we will see most companies calling on the same platform, while a few platforms control core capabilities (Big Pharma, Big Platform, Big Price). Global drug competition and division of labor will become more intense and more complex. For China and the U.S., the most likely scenario is: the U.S. defines Bio-OS, while China participates in Bio-OS engineering, clinical application, and scaling.

Chapter 4: The "Right to Define" and "Right to Price" Drugs May Still Remain in U.S. Hands

In this paradigm revolution in drug innovation, the real industrial power lies not in who does it fastest — but in:

Who defines what a "drug" is? Who defines what "innovation" is? Who decides what clinical evidence counts? Who decides the global payment system?

Once Bio-OS becomes the new infrastructure for drug innovation, in the near term:

• The right to define science remains with the FDA/U.S. research system.

• The right to define platforms remains with U.S. biotech/MNCs.

• The right to define intellectual property remains with the U.S. patent system.

• The right to define clinical value remains with the FDA + global medical systems.

• The right to set commercial prices remains with the U.S. market + MNC global commercial systems.

Despite our vast clinical resources, enormous engineering talent dividend, and superior manufacturing capabilities, if we do not solve foundational scientific research, master source innovation, and address commercial payment issues, we may still find ourselves in the尴尬 position of "participating in the value creation of innovative drugs, but not fully mastering the definition and realization of innovation value."

— Conclusion —

The competition in future drug innovation will no longer be just about "who can discover more new drugs," but "who can build a Bio-OS capable of continuously generating new drugs." The U.S. still holds the right to define this operating system.

China's real opportunity is not to simply replicate the U.S., but to leverage its engineering talent dividend, clinical resources, and IIT advantages to become an indispensable engineering and clinical node within this new operating system.

If China cannot move from "participating in innovation" to "defining innovation," a new paradox may emerge: we increasingly participate in global value creation for new drugs, yet still rely on others to define what innovation is, what a good drug is, and how much that innovation is worth.